Equities

Shield Therapeutics PLC

Shield Therapeutics PLC

Actions
  • Price (EUR)0.028
  • Today's Change0.001 / 3.70%
  • Shares traded0.00
  • 1 Year change-54.84%
  • Beta--
Data delayed at least 15 minutes, as of Nov 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of GBP
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments143.4016
Total Receivables, Net114.524.73
Total Inventory3.201.762.21
Prepaid expenses2.902.50--
Other current assets, total------
Total current assets311223
Property, plant & equipment, net0.670.240.41
Goodwill, net------
Intangibles, net171436
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets492760
LIABILITIES
Accounts payable4.051.74--
Accrued expenses8.779.98--
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.210.110.21
Other current liabilities, total0.701.010.15
Total current liabilities14134.56
Total long term debt207.250
Total debt207.350.21
Deferred income tax------
Minority interest------
Other liabilities, total------
Total liabilities34204.56
SHAREHOLDERS EQUITY
Common stock155.374.57
Additional paid-in capital199169167
Retained earnings (accumulated deficit)(190)(158)(109)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(8.45)(10)(7.66)
Total equity156.5455
Total liabilities & shareholders' equity492760
Total common shares outstanding782267222
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.